SK Biopharmaceuticals Opens Lynx Hub in New Jersey

SK Biopharmaceuticals has opened SK Life Science Lynx, an open innovation hub embedded within its US subsidiary in New Jersey, designed to help Korean pharmaceutical and biotech companies access the US market. Reported on 9 June 2026, the facility connects resident companies with the regulatory, distribution and commercial expertise SK has built through direct US sales of XCOPRI, its epilepsy treatment, while creating early-stage touchpoints for potential licensing-in candidates.

The facility spans roughly 5,680 square feet with 120 pyeong of common workspace, individual offices and meeting rooms, and operates as a consortium with the Korea Trade-Investment Promotion Agency (KOTRA) and the Korea Health Industry Development Institute. Resident Korean biotechs gain access to US business processes, investor and expert networks, and the local commercial knowledge SK has built since launching XCOPRI directly through SK Life Science in May 2020. The US sales operation draws on commercial leadership with prior CNS launch experience at Johnson & Johnson and UCB.

The strategic intent extends beyond providing space. SK Biopharmaceuticals is using Lynx as an early-stage filter to assess Korean drug candidates for US commercial viability, particularly those aligned with its strategic pillars of central nervous system, radiopharmaceutical therapy and targeted protein degradation, with successful candidates progressing toward joint research, strategic investment or licensing-in discussions. Financial firepower for the expansion comes from XCOPRI’s commercial trajectory, with Q1 2026 consolidated revenue reaching 227.9 billion won ($175.3 million), up 57.8% year-on-year, and operating profit rising 249.7% to 89.8 billion won. XCOPRI accounted for 98.3% of total revenue.

The commercial bet here is interesting: SK Biopharmaceuticals is using its hard-won US infrastructure as a discovery platform rather than just a sales vehicle, with the goal of finding its second product among Korean biotechs already pursuing the US market. Whether Lynx delivers actual licensing or investment outcomes will be the real test, particularly given continued investor pressure to diversify beyond XCOPRI dependence.